Fentanyl iontophoretic transdermal system: Phase III started

SymBio began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate SyB P-1501 in about 312 patients. Patients can self-administer up

Read the full 216 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE